Patents by Inventor Donald E. Staunton
Donald E. Staunton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348556Abstract: A non-viral vector, comprising, from 5? to 3?, flanked by two transposon terminal inverted repeats, an inducible promoter, a first coding region comprising a specific combination of genes whose expression is localized to a tumor microenviorment and their function being mediators of CAR persistence and anti-tumor mechanisms to stimulate or enhance a patient anti-tumor response; a second promoter and coding region for expressing one or more artificial immunosurveillance chimeric antigen receptors (AI-CAR), and a truncated CD20 or truncated EGFR safety target. A polycistronic mRNA comprised of a specific combination of transiently expressed anti-tumor mechanisms designed to stimulate a patient anti-tumor response the same as an AI-CAR vector.Type: ApplicationFiled: February 21, 2020Publication date: November 2, 2023Inventors: Donald E. Staunton, John M. Luk, John M. Harlan, David Kin Jin
-
Publication number: 20220185882Abstract: The application provides non-viral vector, comprising an artificial immunosurveillance chimeric antigen receptor (AI-CAR) expression cassette flanked by two transposons or viral terminal repeats (IR), wherein the AI-CAR expression cassette comprises an inducible gene expression unit and a CAR expression unit.Type: ApplicationFiled: February 21, 2020Publication date: June 16, 2022Inventors: Donald E. Staunton, John M. Luk, John M. Harlan
-
Publication number: 20150010536Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.Type: ApplicationFiled: November 22, 2013Publication date: January 8, 2015Applicant: CisThera, IncorporatedInventors: Donald E. Staunton, Maximiliano Vasquez
-
Patent number: 7981415Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.Type: GrantFiled: November 20, 2008Date of Patent: July 19, 2011Assignee: Cisthera, Inc.Inventors: Donald E. Staunton, Maximiliano Vasquez
-
Publication number: 20100254979Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.Type: ApplicationFiled: March 8, 2010Publication date: October 7, 2010Applicant: CISTHERA, INCORPORATEDInventors: Donald E. Staunton, Maximiliano Vasquez
-
Patent number: 7771720Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.Type: GrantFiled: September 5, 2008Date of Patent: August 10, 2010Assignee: CisThera, Inc.Inventors: Donald E. Staunton, Maximiliano Vasquez
-
Publication number: 20090136500Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.Type: ApplicationFiled: November 20, 2008Publication date: May 28, 2009Applicant: CISTHERA INCORPORATEDInventors: Donald E. Staunton, Maximiliano Vasquez
-
Publication number: 20090081239Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.Type: ApplicationFiled: September 5, 2008Publication date: March 26, 2009Applicant: CisThera IncorporatedInventors: Donald E. Staunton, Maximiliano Vasquez
-
Patent number: 6797270Abstract: The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.Type: GrantFiled: April 11, 1995Date of Patent: September 28, 2004Assignee: Center for Blood Research, Inc.Inventors: Timothy A. Springer, Donald E. Staunton
-
Patent number: 6777191Abstract: The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.Type: GrantFiled: June 7, 1995Date of Patent: August 17, 2004Assignee: Center for Blood Research, Inc.Inventors: Timothy A. Springer, Donald E. Staunton
-
Publication number: 20030088061Abstract: Methods of modulating binding between an &agr;/&bgr; protein and a binding partner are provided, along with methods of identifying modulators and their use.Type: ApplicationFiled: October 12, 2001Publication date: May 8, 2003Inventor: Donald E. Staunton
-
Publication number: 20030044958Abstract: The present invention provides purified and isolated polynucleotides encoding IRP polypeptides which regulate &bgr;2 and &bgr;7 integrins and which are contemplated to participate in integrin signaling and/or recycling pathways. Also provided are methods for identifying modulators of IRP activities and methods for identifying other proteins which interact with IRP polypeptides in signaling pathways. Modulators of IRP interactions are contemplated to be useful, for example, in monitoring and treating inflammatory processes involving leukocytes.Type: ApplicationFiled: March 26, 2001Publication date: March 6, 2003Applicant: ICOS CorporationInventors: Donald E. Staunton, Brian P. Lispky
-
Patent number: 6511664Abstract: The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.Type: GrantFiled: February 13, 1996Date of Patent: January 28, 2003Assignee: Dana Farber Cancer InstituteInventors: Timothy A. Springer, Donald E. Staunton, Michael L. Dustin
-
Publication number: 20020177231Abstract: Disclosed are novel leupaxin polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cell transformed with the polynucleotides, methods to produce the polypeptides, antibodies and binding partners specific for the polypeptides, methods to identify modulators of the polypeptides, and methods to identify modulators of polypeptide expression.Type: ApplicationFiled: December 15, 1998Publication date: November 28, 2002Inventors: DONALD E. STAUNTON, BRIAN P. LIPSKY, PATRICK W. GRAY
-
Patent number: 6436403Abstract: The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.Type: GrantFiled: June 7, 1995Date of Patent: August 20, 2002Assignee: Center for Blood Research, Inc.Inventors: Timothy A. Springer, Donald E. Staunton
-
Patent number: 6210914Abstract: The present invention provides purified and isolated polynucleotides encoding IRP (Integrin Regulatory Protein) polypeptides which regulate &bgr;2 and &bgr;7 integrins and which are contemplated to participate in integrin signaling and/or recycling pathways. Also provided are methods for identifying modulators of IRP activities and methods for identifying other proteins which interact with IRP polypeptides in signaling pathways. Modulators of IRP interactions are contemplated to be useful, for example, in monitoring and treating inflammatory processes involving leukocytes.Type: GrantFiled: February 13, 1998Date of Patent: April 3, 2001Assignee: ICOS CorporationInventors: Donald E. Staunton, Brian P. Lispky
-
Patent number: 5958705Abstract: The present invention provides purified and isolated polynucleotides encoding IRP (integrin regulatory protein) polypeptides which regulate .beta..sub.2 and .beta..sub.7 integrins and which are contemplated to participate in integrin signaling and/or recycling pathways. Also provided are methods for identifying modulators of IRP activities and methods for identifying other proteins which interact with IRP polypeptides in signaling pathways. Modulators of IRP interactions are contemplated to be useful, for example, in monitoring and treating inflammatory processes involving leukocytes.Type: GrantFiled: April 15, 1997Date of Patent: September 28, 1999Assignee: ICOS CorporationInventors: Donald E. Staunton, Brian P. Lispky
-
Patent number: 5948891Abstract: The present invention relates to purified and isolated polynucleotides encoding a polypeptide which specifically bind to a cytoplasmic portion of an integrin. Specifically, the invention provides a FLP-1-encoding polynucleotide and the polypeptide product of the gene. Expression vectors comprising the polynucleotide, antibodies which recognize the polypeptide, hybridomas which secrete the antibodies, and method to identify modulators of interaction of the polypeptide with .beta..sub.7 subunits sequences are also provided.Type: GrantFiled: January 6, 1997Date of Patent: September 7, 1999Assignee: ICOS CorporationInventors: Donald E. Staunton, Edith A. Salot Harris
-
Patent number: 5922570Abstract: The present invention relates to purified and isolated polynucleotides encoding a polypeptide which specifically bind to a cytoplasmic portion of an integrin. Specifically, the invention provides a FLP-1-encoding polynucleotide and the polypeptide product of the gene. Expression vectors comprising the polynucleotide, antibodies which recognize the polypeptide, hybridomas which secrete the antibodies, and method to identify modulators of interaction of the polypeptide with .beta..sub.7 subunits sequences are also provided.Type: GrantFiled: January 5, 1996Date of Patent: July 13, 1999Assignee: ICOS CorporationInventors: Donald E. Staunton, Edith Salot Harris
-
Patent number: 5693483Abstract: The present invention relates to methods to identify modulators of integrin binding and/or signalling activity. Specifically the invention relates to a method to identify compounds which can alter the interaction between the cytoplasmic domain of a .beta..sub.1 integrin and a proteasome subunit protein.Type: GrantFiled: January 5, 1996Date of Patent: December 2, 1997Assignee: ICOS CorporationInventors: Donald E. Staunton, Edith Salot Harris